Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 449

Results For "MS"

5457 News Found

Tata Elxsi has unveiled TEngage, a digital health platform
Digitisation | March 19, 2022

Tata Elxsi has unveiled TEngage, a digital health platform

In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check


USFDA approves Marinus’ treatment for genetic disorder
Drug Approval | March 19, 2022

USFDA approves Marinus’ treatment for genetic disorder

First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older


Thirty five generic manufacturers sign agreements with MPP for Paxlovid
News | March 18, 2022

Thirty five generic manufacturers sign agreements with MPP for Paxlovid

The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris


AstraZeneca launches global R&D post-doctoral challenge
News | March 18, 2022

AstraZeneca launches global R&D post-doctoral challenge

Successful proposals will secure fully funded postdoctoral research positions


Sanofi moves forward with EUROAPI listing on Euronext Paris
Biotech | March 18, 2022

Sanofi moves forward with EUROAPI listing on Euronext Paris

EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions


Community approach crucial to stamp out diseases
Public Health | March 17, 2022

Community approach crucial to stamp out diseases

The Karnataka Health Promotion Trust held a day-long session in New Delhi to address health care challenges


USFDA approves Rinvoq for ulcerative colitis
Drug Approval | March 17, 2022

USFDA approves Rinvoq for ulcerative colitis

First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology


Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
Drug Approval | March 17, 2022

Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer

First PARP inhibitor to demonstrate overall survival benefit in early breast cancer


BASF and Beyond Suncare renew their cooperation to protect people with albinism in Africa
Sustainability | March 17, 2022

BASF and Beyond Suncare renew their cooperation to protect people with albinism in Africa

Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation


Beghou Consulting strengthens advanced analytics and data science team in Pune
News | March 17, 2022

Beghou Consulting strengthens advanced analytics and data science team in Pune

Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies